• MDL 28170: A Selective Calpain Inhibitor Workflow

  2026-08-12

  MDL 28170 combines nanomolar calpain inhibition with cell permeability and brain exposure, making it useful for mechanistic neuroprotection studies and injury models. This guide translates recent BDNF/TrkB findings into practical assay design, controls, optimization steps, and cross-domain applications.

• Pazopanib Hydrochloride: From Target to Translation

  2026-08-11

  A thought-leadership guide to using Pazopanib Hydrochloride (GW786034) as a mechanistically informed reference compound in cancer research, with emphasis on response metrics, assay design, translational positioning, and clinical context.

• UK-5099 Whole-Blood Immunometabolism Workflow

  2026-08-10

  Use UK-5099, also called PF-1005023, to test how mitochondrial pyruvate entry shapes cytokine responses, cellular energy status, and glucose handling. This workflow connects standardized whole-blood stimulation with orthogonal mitochondrial, beta-cell, and in vivo validation while emphasizing solvent control, donor variability, and endpoint-specific troubleshooting.

• Calpain Inhibitor I, ALLN: Protocol Guide

  2026-08-09

  Calpain Inhibitor I, ALLN (SKU A2602) provides a dossier-defined approach for studying calpain and cathepsin protease activity in apoptosis, inflammation, and ischemia-reperfusion workflows. It is intended for controlled scientific experiments only; it is water-insoluble, requires solvent-based preparation, and should not be used for diagnostic, therapeutic, or medical applications.

• H 89 2HCl: Mapping PKA Signals in Striatal Assays

  2026-08-08

  H 89 2HCl enables controlled interrogation of cAMP-dependent protein kinase activity without assuming that every neuronal phenotype is PKA-driven. This article connects its pharmacology with Neuroligin 1–D2-MSN research and provides an assay strategy for separating PKA, PKC, and broader kinase effects.

• H3K18 Lactylation Drives NOD2 in Bilirubin Injury

  2026-08-07

  Li et al. identify a glycolysis-linked H3K18 lactylation–NOD2 pathway that promotes astrocyte pyroptosis and neuroinflammation during bilirubin encephalopathy. Their combined rat, primary astrocyte, CUT&Tag, and RNA-seq analyses connect metabolic remodeling to epigenetic control of inflammatory gene expression, while also defining important limits for translation and follow-up intervention studies.

• Epalrestat Activates KEAP1/Nrf2 for Neuroprotection in Parki

  2026-08-07

  Jia et al. demonstrate that Epalrestat, a clinically established aldose reductase inhibitor, directly binds KEAP1 and activates the Nrf2 pathway to protect dopaminergic neurons in Parkinson’s disease models. This work clarifies a previously unresolved mechanism and suggests repurposing Epalrestat for neurodegenerative disease research.

• Ciclesonide and Desisobutyryl-Ciclesonide: Mechanistic Preci

  2026-08-06

  Explore the advanced pharmacology of Ciclesonide and desisobutyryl-ciclesonide in respiratory disease research. This article offers a deep dive into their activation, receptor binding, and unique applications beyond standard asthma models.

• ALDOB K87 Lactylation Orchestrates Mitochondrial Fission in

  2026-08-06

  A recent study demonstrates that ALDOB K87 lactylation drives mitochondrial fission and metabolic reprogramming in pulmonary hypertension (PH), connecting altered glycolytic metabolism to abnormal vascular remodeling. These findings highlight a novel metabolic-structural axis and suggest new molecular targets for PH intervention.

• Prostaglandin E2 in Inflammation Research: Protocols & Solut

  2026-08-05

  Prostaglandin E2 (PGE2) is a versatile tool for dissecting immune regulation, gastrointestinal mucosal protection, and inflammation mechanisms. This article delivers workflow enhancements, troubleshooting strategies, and data-driven insights to maximize the impact of APExBIO’s PGE2 in applied biomedical research.

• Butylated Hydroxyanisole (BHA): Strategic Insights for Trans

  2026-08-05

  A thought-leadership article that bridges mechanistic understanding and translational guidance, exploring how Butylated Hydroxyanisole (BHA) empowers researchers to precisely modulate oxidative stress, validate peptide modifications, and advance redox biology in complex cellular models. This piece synthesizes current literature, comparative workflows, and advanced protocol considerations, positioning BHA as a cornerstone for innovative biomedical research.

• NHS-Biotin: Catalyzing Precision in Multimeric Protein Engin

  2026-08-04

  This thought-leadership article explores how NHS-Biotin (N-hydroxysuccinimido biotin) is redefining protein engineering—bridging mechanistic insight, translational strategy, and the latest advances in multimeric nanobody assembly. Drawing on the recent peptidisc-assisted clustering paradigm, the article provides actionable guidance for researchers seeking to exploit biotinylation chemistries for advanced detection, purification, and functional engineering of proteins, with a focus on minimizing steric hindrance and maximizing intracellular utility. Distinct from conventional product pages, this discussion contextualizes the strategic value of APExBIO's NHS-Biotin within the evolving landscape of multispecific and multimeric protein therapeutics.

• Triptolide (PG490): Precision Inhibitor for Genome and Cance

  2026-08-04

  Triptolide (PG490) is a nanomolar-range transcriptional inhibitor renowned for its dual action against IL-2/NF-κB signaling and metastatic pathways. This article delivers actionable workflows and troubleshooting strategies to maximize reproducibility and impact in cancer and developmental biology research.

• Selonsertib (GS-4997): Applied ASK1 Inhibition in NAFLD Rese

  2026-08-03

  Selonsertib (GS-4997) from APExBIO enables targeted interrogation of oxidative stress and autophagy pathways in metabolic liver disease models. This article distills cutting-edge workflows, troubleshooting strategies, and actionable assay enhancements for studies of inflammation, fibrosis, and diabetic kidney disease.

• Naloxone Hydrochloride: Opioid Receptor Antagonist for Resea

  2026-08-03

  Naloxone hydrochloride is a potent opioid receptor antagonist that blocks μ-, δ-, and κ-opioid receptors, reversing opioid effects and modulating neural and immune pathways. APExBIO’s high-purity formulation enables reproducible research in opioid addiction, receptor signaling, and neural stem cell proliferation assays.

432 records 7/29 page Previous Next First page 上5页 678910 下5页 Last page